COMP <GO>

AMLX vs OGN // EV/EBITDA & P/E VALUATION

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Organon & Co. (NYSE) • 15-METRIC TALLY: AMLX 0 — OGN 6

■ METRIC PARITY

LAST: $28.68 (+2.17%) • MKT CAP: $3.60B

valuation

—

LAST: $13.81 (+0.22%) • MKT CAP: $3.63B

valuation

—

15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. OGN) EMERALD CELL = QUANTITATIVE EDGE

INSTITUTIONAL METRIC	AMLX	OGN	SPREAD (A - B)	ADVANTAGE	DEDICATED URL
Gross Profit Margin	—	53.30%	—	TIE	/gross-margins <GO>
Return on Invested Capital (ROIC)	-35.00%	24.90%	-59.90	OGN	/roic <GO>
EV/EBITDA & P/E Valuation ACTIVE	—	—	—	TIE	/valuation <GO>
Free Cash Flow Yield	-3.43%	14.83%	-18.26	OGN	/fcf-yield <GO>
Operating Margin	—	—	—	TIE	/operating-margins <GO>
Net Profit Margin	—	3.00%	—	TIE	/net-margins <GO>
Revenue Growth (YoY)	—	-2.90%	—	TIE	/revenue-growth <GO>
Dividend Yield & FCF Payout Safety	0.00%	2.43%	-2.43	OGN	/dividend-safety <GO>
Altman Z-Score & Debt/Equity	—	—	—	TIE	/balance-sheet <GO>
Piotroski F-Score Quality	3/9	6/9	-3.00	OGN	/piotroski-score <GO>
Options Implied Move & Put/Call Skew	—	—	—	TIE	/options-implied-move <GO>
RSI-14 & 200D SMA Momentum	51.9	67.8	-15.87	OGN	/rsi-technicals <GO>
10Y Yield & FRED Macro Beta	—	—	—	TIE	/macro-sensitivity <GO>
Forward P/E Multiple	—	18.0x	—	TIE	/forward-pe <GO>
Enterprise Scale & Market Cap	$3.60B	$3.63B	-$28.5M	OGN	/market-cap <GO>

5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY

FISCAL YEAR	AMLX REV	OGN REV	AMLX GROSS %	OGN GROSS %	AMLX FCF	OGN FCF
FY 2025	$0	$6.22B	—	53.3%	-$123.5M	$538.0M
FY 2024	$87.4M	$6.40B	93.2%	58.0%	-$167.8M	$764.0M
FY 2023	$380.8M	$6.26B	—	—	$11.9M	$799.0M

FRED MACRO REGIME CORRELATION COMPARISON PEARSON r

AMLX // BETA —

OGN // BETA —